🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. appliedclinicaltrialsonline.com/view/apex-tria…

Thierry Escudier, portfolio lead, The Pistoia Alliance , highlights where #regulatory agencies currently stand on #sustainability in #clinicaltrials and how #pharma companies are looking to reduce their carbon footprint. appliedclinicaltrialsonline.com/view/prepared-…

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in slowing disability progression compared to the currently approved 600mg dose. appliedclinicaltrialsonline.com/view/high-dose…

The Top Five Myths About eCOAs in 2025 Are eCOA myths holding your trials back? Join our live virtual event as industry experts debunk the top 5 eCOA myths of 2025, sharing insights to help you make smarter decisions. Don’t miss it! Register now: hubs.li/Q03dkLmY0

Why investing in truly effective training from the outset can pay off exponentially for clinical teams—and serve as a strategic advantage. appliedclinicaltrialsonline.com/view/the-compo…

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients. appliedclinicaltrialsonline.com/view/digital-m…

Thierry Escudier, portfolio lead, The Pistoia Alliance, talks the current landscape of #sustainability in #clinicaltrials and how stakeholders are beginning to pay more attention to carbon footprint amid increasing protocol complexity. appliedclinicaltrialsonline.com/view/new-era-s…

The challenges, opportunities, and strategic outlook for oncology research centers. appliedclinicaltrialsonline.com/view/scaling-e…

Anticipating divestment, reallocation of investments, and retrenchment. Ken Getz, MBA, Executive Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine appliedclinicaltrialsonline.com/view/the-hard-…

Study uncovers insights on the impact on safety, patient enrollment/retention, and compliance. appliedclinicaltrialsonline.com/view/benchmark…

Thierry Escudier, portfolio lead, The Pistoia Alliance , highlights the need for maintaining #dataprivacy in a highly regulated #clinicalresearch industry. appliedclinicaltrialsonline.com/view/maintaini…

The future of clinical trial design involves incorporating the patient experience into strategic asset planning. appliedclinicaltrialsonline.com/view/tapping-t…

At SCOPE Summit 2025, uMotif CEO Steve Rosenberg shared insights on transforming the patient and site experience in clinical trials. Learn how innovative strategies are shaping the future of clinical trials in this exclusive booth video. Watch the Video: hubs.li/Q03d6mv80

Innovative Clinical Outcome Assessment (COA) Solutions for Obesity Trials: Measuring Matters Ready to elevate your clinical trials? Join our live webinar to see how COA solutions and connected devices enhance efficiency and outcomes. Register now: hubs.li/Q03fjtvP0

Innovative Clinical Outcome Assessment (COA) Solutions for Obesity Trials: Measuring Matters Join our live webinar to see how innovative COA solutions transform obesity trials, boosting efficiency and speeding treatments. Register now: hubs.li/Q03fjBPl0

Complex Trials, Clear Budgets: Accelerating Budget Finalization in Global Clinical Trials Clinical trial budgets are more complex than ever. Join our webinar to explore strategies that speed budget finalization and streamline study start-up. Register now: hubs.li/Q03mN2KQ0

Complex Trials, Clear Budgets: Accelerating Budget Finalization in Global Clinical Trials Still finalizing clinical trial budgets manually? Join this live webinar to discover how technology is transforming clinical trial budgeting. Register now: hubs.li/Q03mN4cX0

\Mark Rodgers discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access Download podcast and Q&A: hubs.li/Q03pkPKJ0